ImmunityBio, Inc.
IBRX
$2.13
$0.010.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 81.92M | 56.09M | 30.66M | 14.19M | 7.12M |
| Total Other Revenue | 639.00K | 510.00K | 563.00K | 595.00K | 388.00K |
| Total Revenue | 82.56M | 56.60M | 31.22M | 14.75M | 7.33M |
| Cost of Revenue | 371.00K | 194.00K | 58.00K | -- | -- |
| Gross Profit | 82.18M | 56.41M | 31.16M | 14.75M | 7.33M |
| SG&A Expenses | 157.41M | 157.04M | 163.85M | 173.08M | 164.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 343.30M | 341.97M | 344.64M | 358.93M | 366.62M |
| Operating Income | -260.75M | -285.37M | -313.42M | -344.18M | -359.28M |
| Income Before Tax | -348.69M | -367.14M | -409.42M | -413.65M | -587.92M |
| Income Tax Expenses | 0.00 | 35.00K | -234.00K | -- | -40.00K |
| Earnings from Continuing Operations | -348.69 | -367.17 | -409.18 | -413.65 | -587.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 77.00K | 79.00K | 80.00K | 81.00K | 86.00K |
| Net Income | -348.62M | -367.09M | -409.10M | -413.56M | -587.79M |
| EBIT | -260.75M | -285.37M | -313.42M | -344.18M | -359.28M |
| EBITDA | -244.95M | -269.07M | -296.59M | -326.63M | -341.30M |
| EPS Basic | -0.41 | -0.46 | -0.55 | -0.60 | -0.87 |
| Normalized Basic EPS | -0.25 | -0.29 | -0.34 | -0.37 | -0.54 |
| EPS Diluted | -0.42 | -0.49 | -0.59 | -0.64 | -0.89 |
| Normalized Diluted EPS | -0.25 | -0.29 | -0.34 | -0.37 | -0.54 |
| Average Basic Shares Outstanding | 3.42B | 3.17B | 2.97B | 2.79B | 2.73B |
| Average Diluted Shares Outstanding | 3.42B | 3.17B | 2.97B | 2.79B | 2.73B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |